Back to top
more

Medpace (MEDP)

(Delayed Data from NSDQ)

$319.56 USD

319.56
307,956

+5.34 (1.70%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $319.71 +0.15 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 250)

Industry: Medical Services

Better trading starts here.

Zacks News

CVS Health (CVS) Q3 Earnings Top Estimates, 2021 EPS View Up

Strength in all three operating segments drove CVS Health's (CVS) revenues in the third quarter of 2021.

Exact Sciences (EXAS) Q3 Earnings and Revenues Beat Estimates

Exact Sciences' (EXAS) legacy Screening business registered an improvement in revenues during the third quarter on strong contributions from Cologuard volume growth.

Myriad Genetics (MYGN) Q3 Loss Wider Than Expected, Revenues Top

Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment drove Q3 sales despite a challenging business environment.

Henry Schein (HSIC) Q3 Earnings Top Estimates, 2021 EPS View Up

Strengthening demand in the global dental and medical markets drove Henry Schein's (HSIC) revenues in the third quarter.

Hologic (HOLX) Q4 Earnings Surpass Estimates, 2022 View Dull

Impressive performance by the Breast Health and GYN Surgical segments drives Hologic's (HOLX) fiscal fourth-quarter revenues.

Bio-Rad (BIO) Q3 Earnings Surpass Estimates, 2021 View Raised

Strength in the Life Science and Clinical Diagnostics segments drove Bio-Rad's (BIO) revenues in the third quarter.

Is Invesco S&P MidCap 400 Pure Growth ETF (RFG) a Strong ETF Right Now?

Smart Beta ETF report for RFG

Medpace (MEDP) Tops Q3 Earnings and Revenue Estimates

Medpace (MEDP) delivered earnings and revenue surprises of 20.56% and 1.20%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Medpace (MEDP) Q3 Earnings Expected to Decline

Medpace (MEDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Medpace (MEDP) Moves 3.3% Higher: Will This Strength Last?

Medpace (MEDP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Medpace (MEDP) Moves to Buy: Rationale Behind the Upgrade

Medpace (MEDP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Medpace (MEDP) Q2 Earnings and Revenues Beat Estimates

Medpace (MEDP) delivered earnings and revenue surprises of 8.16% and 2.62%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Medpace (MEDP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Medpace (MEDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Medpace (MEDP) Q1 Earnings Surpass Estimates

Medpace (MEDP) delivered earnings and revenue surprises of 15.84% and -1.90%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Medpace (MEDP) Earnings Expected to Grow: Should You Buy?

Medpace (MEDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Strength Seen in Medpace (MEDP): Can Its 3.5% Jump Turn into More Strength?

Medpace (MEDP) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Medpace (MEDP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Medpace (MEDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Teladoc (TDOC) and Dexcom Offer New Solutions for Diabetes

Teladoc (TDOC) and Dexcom jointly provide solutions for patients with Type 2 diabetes, a common lifestyle-induced malady.

Medpace (MEDP) Tops Q3 Earnings and Revenue Estimates

Medpace (MEDP) delivered earnings and revenue surprises of 4.63% and 2.74%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Medpace (MEDP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Medpace (MEDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Top Ranked Momentum Stocks to Buy for August 28th

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, August 28th.

Top Ranked Momentum Stocks to Buy for August 26th

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, August 26th.

Top Ranked Momentum Stocks to Buy for August 24th

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 24th.

Medpace (MEDP) is a Great Momentum Stock: Should You Buy?

Does Medpace (MEDP) have what it takes to be a top stock pick for momentum investors? Let's find out.

Top Ranked Momentum Stocks to Buy for August 20th

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 20th.